12:05 , Jun 22, 2018 |  BioCentury  |  Finance

Regenerating eastward

Having capitalized on the cell therapy expertise and manufacturing incentives of its European home base, Promethera Biosciences S.A. is expanding to Japan to tap the commitment to regenerative medicines among investors, pharmas and regulators. After...
13:40 , Apr 13, 2018 |  BC Week In Review  |  Company News

Promethera acquires antibody play Baliopharm

Liver disease company Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium) said it acquired antibody developer Baliopharm AG (Basel, Switzerland). Promethera declined to disclose financial details. Promethera also raised €9.3 million ($11.4 million) on April 10 through the...
06:45 , Apr 10, 2018 |  BC Extra  |  Company News

Promethera acquires antibody play Baliopharm

Liver disease company Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium) said it acquired antibody developer Baliopharm AG (Basel, Switzerland). Promethera declined to disclose financial details. Promethera also raised €9.3 million ($11.4 million) through the sale of convertible...
15:03 , Mar 1, 2018 |  BC Innovations  |  Translation in Brief

A path less traveled

A team from PSL Research University has shown how a nitric oxide (NO)-donating compound steers TNFα signaling away from a pro-survival pathway towards one that promotes death in cancer cells. The findings suggest NO-donors could...
01:53 , Jan 25, 2018 |  BC Innovations  |  Translation in Brief

No TNFα for transplants

A University of Toronto team has shown that inhibiting TNFα enhances the engraftment success of hematopoietic stem cell transplants in mice and plans to test the strategy in the clinic using Enbrel etanercept within a...
23:38 , Oct 24, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Cell models A biobank of insertional mutagenesis-derived haploid mouse ESCs could be used to link genes to disease-related phenotypes in homogeneous cell populations. The biobank consists of over 100,000 haploid mouse ESCs with genetically barcoded...
07:00 , May 12, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); tumor necrosis factor receptor 1 (TNFRSF1A; TNFR1; CD120a); HECT domain and ankyrin

Cancer INDICATION: Colorectal cancer; cancer Mouse studies suggest inhibiting TNFRSF1A or RIPK3 could help treat colon and other cancers harboring loss-of-function HACE1 mutations. In a mouse model of HACE1-mutant colon cancer, systemic knockout of TNFRSF1A or RIPK3...
08:00 , Jan 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin 4 (IL-4); IL-10; IL-22; tumor necrosis factor α (TNFα)

Autoimmune disease INDICATION: Psoriasis Cell culture and mouse studies suggest cells engineered to secrete the anti-inflammatory cytokines IL-4 and IL-10 in response to the pro-inflammatory cytokines TNFα and IL-22 could help treat psoriasis. Human embryonic kidney cells...
08:00 , Jan 14, 2016 |  BC Innovations  |  Tools & Techniques

"And" not "or" in psoriasis

Diseases with dynamic, irregular flare-ups like psoriasis may now have a therapeutic platform that can automatically keep up. A Swiss group has designed implantable cells that can detect and treat psoriatic inflammation using cytokine-based Boolean...
07:00 , Aug 29, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Various Autoimmune disease; cachexia Tumor necrosis factor-a (TNF-a) Biochemical and...